Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report

Mingzi Zhang; Qi Li; Yehong Sun

doi:10.7555/JBR.36.20220065

Volume 36 Issue 6

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2022 > 36(6): 440-445

Mingzi Zhang, Qi Li, Yehong Sun. Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report[J]. The Journal of Biomedical Research, 2022, 36(6): 440-445. doi: 10.7555/JBR.36.20220065

Citation:

Mingzi Zhang, Qi Li, Yehong Sun. Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report[J]. The Journal of Biomedical Research, 2022, 36(6): 440-445. doi: 10.7555/JBR.36.20220065

Citation:

PDF( 3789 KB)

Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report

doi: 10.7555/JBR.36.20220065

Mingzi Zhang¹,
Qi Li^{2
,
,},
Yehong Sun^{1
,
,}

1.
Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, China
2.
Department of Internal Medicine-Oncology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China

More Information

Corresponding author: Qi Li, Department of Internal Medicine-Oncology, Shenzhen Traditional Chinese Medicine Hospital, 1 Fuhua Road, Shenzhen, Guangdong 518033, China. E-mail: doctorliqi@126.com; Yehong Sun, Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, 1 Fuhua Road, Shenzhen, Guangdong 518033, China. Tel: +86-755-88605070, E-mail: syehong@163.com
Received: 2022-03-24
Revised: 2022-05-07
Accepted: 2022-05-13

Published: 2022-06-28

Issue Date: 2022-11-28

Abstract

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plays an important role in cancer therapy. However, EGFR is highly expressed in the skin and gives rise to one of the most concerning issues for the EGFR-TKI treatment, namely skin toxicity. Antibiotics and corticosteroids are usually used to treat the EGFR inhibitor-associated skin rash, with prominent side effects over long-time use. Pien Tze Huang (PZH) Unguentum Compositum is a traditional product for external application which is made of traditional Chinese medicine and oil base. Herein, we reported the case of a 50-year-old man who presented with skin rash on the face, head, and back induced by an EGFR-TKI named erlotinib. By using PZH Unguentum Compositum, we observed that the skin rash was mitigated and eventually disappeared. This case report suggests that PZH Unguentum Compositum may be an effective therapy in treating skin rash caused by EGFR-TKI with fewer side effects.
- epidermal growth factor receptor,
- tyrosine kinase inhibitor,
- skin rash,
- Pien Tze Huang,
- erlotinib

CLC number: R275.9, Document code: B
The authors reported no conflict of interests.

FullText(HTML)

References(14)

References

[1]	Jurišić V, Obradovic J, Pavlović S, et al. Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation[J]. Anal Cell Pathol (Amst), 2018, 2018: 6192187. doi: 10.1155/2018/6192187
[2]	Jurisic V, Vukovic V, Obradovic J, et al. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis[J]. J Oncol, 2020, 2020: 1973241. doi: 10.1155/2020/1973241
[3]	Xia G, Zeng Y, Fang Y, et al. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI[J]. Cancer Biol Med, 2014, 11(4): 270–276. doi: 10.7497/j.issn.2095-3941.2014.04.006
[4]	Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future[J]. Expert Rev Anticancer Ther, 2013, 13(6): 745–758. doi: 10.1586/era.13.47
[5]	Melosky B, Leighl NB, Rothenstein J, et al. Management of EGFR TKI-induced dermatologic adverse events[J]. Curr Oncol, 2015, 22(2): 123–132. doi: 10.3747/co.22.2430
[6]	Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor[J]. Jpn J Clin Oncol, 2016, 46(4): 291–298. doi: 10.1093/jjco/hyv207
[7]	Zhang X, Zhang Q, Huang L, et al. Pien-Tze-Huang attenuates neuroinflammation in cerebral ischaemia-reperfusion injury in rats through the TLR4/NF-κB/MAPK pathway[J]. Pharm Biol, 2021, 59(1): 826–837. doi: 10.1080/13880209.2021.1942926
[8]	Zeng M, Zhu J, Yang G. The clinical observation of Pien Tze Huang Unguentum Compositum Cream combined with Lankefuning on rosacea[J]. Chin J Aesthetic Med (in Chinese), 2012, 21(18): 291. http://www.cnki.com.cn/Article/CJFDTotal-MRYX201218293.htm
[9]	Zhu H, Li T, Du Y, et al. Pancreatic cancer: challenges and opportunities[J]. BMC Med, 2018, 16(1): 214. doi: 10.1186/s12916-018-1215-3
[10]	Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625–635. doi: 10.1016/S1470-2045(19)30035-X
[11]	Lee HJ, Jeong GH, Li H, et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(20): 6232–6244. doi: 10.26355/eurrev_202110_26993
[12]	Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitors in oncology[J]. Drug Saf, 2019, 42(2): 181–198. doi: 10.1007/s40264-018-0772-x
[13]	Arrieta O, Vega-González MT, López-Macías D, et al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients[J]. Lung Cancer, 2015, 88(3): 282–288. doi: 10.1016/j.lungcan.2015.03.019
[14]	Chen Z. Pien Tze Huang (PZH) as a multifunction medicinal agent in traditional Chinese medicine (TCM): a review on cellular, molecular and physiological mechanisms[J]. Cancer Cell Int, 2021, 21(1): 146. doi: 10.1186/s12935-021-01785-3